OBJECTIVES: To evaluate utilisation of drugs involved in treatment of NSCLC, its consumption in terms of expenditures units and number of packages prescribed in Slovakia within 2008 -2011. METHODS: Statistical analysed data were abstracted from State Institute for Drug Control SR, studied in accordance with financial units (€) and number of packages prescribed every year. RESULTS: ATC  L01 – antineoplastic agents is the one most prescribed out off all anticancer drugs (593 067 packages prescribed in 2011, 105 786 256,10 €). From L01XA platinum cytostatics – cisplatina is the one most prescribed, with decreasing tendency in financial expenditures spent (45 965 pcgs, 344 601,70 € in 2008 and 56 584 pcgs, 229 525,80 € in 2011) compared to the least prescribed and most expensive oxiplatina. L01CD taxans – paclitaxel and docetaxel has decreasing tendency in number of packages prescribed and in financial expenditures. L01BC – the most prescribed fluorouracil has decreasing tendency, the prescription of gemcitabin stagnates, utilization of kapecitabin increases in number of packages and in financial units. L01XC monoclonal antibodies – prescription of bevacizumab had increasing tendency until 2010 (13 405 pcgs, 11 339 764,50 € in 2008, 24 028 pcgs, 18 256 481,00 € in 2010 ), in 2011 prescription of cetuximab was higher than bevacizumab, and less money was spent (cetuximab: 28 772 pcgs, 5 385 830,90€, bevacizumab: 22 661 pcgs, 17 045 495,70€). L01XE - inhibitors of protein kinase – erlotinib has increasing tendency in number of packages prescribed and in financial expenditures (1 265  pcgs, 2 895 154,30 € in 2008, 2 071 pcgs, 3 687 581,00 € in 2011), tendency of gefitinib since 2010 when it entered the market is increasing, but it still did not overtook erlotinib (248 pcgs, 545 600,00 € in 2011). CONCLUSIONS: This study proved high economic burden and continually rising amount of expenditures on antineoplastic agents, used also in treatment of NSCLC